Literature DB >> 8758897

Distinct tumorigenic potential of abl and raf in B cell neoplasia: abl activates the IL-6 signaling pathway.

D M Hilbert1, T S Migone, M Kopf, W J Leonard, S Rudikoff.   

Abstract

The development of murine plasma cell tumors induced by raf/myc containing retroviruses is facilitated by T cells and completely dependent on IL-6. To determine whether kinases with differing specificities reflect alternative biochemical pathways in B cell tumorigenesis, we have employed an abl/myc containing retrovirus to assess neoplastic development. In contrast with raf/myc, abl/myc disease is T cell and IL-6 independent. An examination of the IL-6 signal transduction pathway reveals that this pathway, as defined by activation of Stat3, is inducible by IL-6 in raf/myc tumors but constitutively activated in abl/myc tumors. These findings provide a mechanism for the derivation of cytokine-independent plasma cell tumors and suggest that both IL-6-dependent and independent tumors may arise in vivo depending on the particular mutational events incurred during tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8758897     DOI: 10.1016/s1074-7613(00)80312-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  9 in total

1.  IL-6 transgenic mouse model for extraosseous plasmacytoma.

Authors:  Alexander L Kovalchuk; Joong Su Kim; Sung Sup Park; Allen E Coleman; Jerrold M Ward; Herbert C Morse; Tadamitsu Kishimoto; Michael Potter; Siegfried Janz
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.

Authors:  J J O'Shea; L D Notarangelo; J A Johnston; F Candotti
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

3.  The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice.

Authors:  T R Rosean; V S Tompkins; A K Olivier; R Sompallae; L A Norian; H C Morse; T J Waldschmidt; S Janz
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

Review 4.  STAT signaling in the pathogenesis and treatment of cancer.

Authors:  D A Frank
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

5.  Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice.

Authors:  G Lattanzio; C Libert; M Aquilina; M Cappelletti; G Ciliberto; P Musiani; V Poli
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

6.  Hematologic neoplasias and acromegaly.

Authors:  Flavia Regina P Barbosa; Leonardo Vieira Neto; Giovanna Aparecida B Lima; Luiz Eduardo Wildemberg; Rodrigo Portugal; Monica R Gadelha
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

7.  Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in normal, self-renewing B-1 cells but only inducibly expressed in conventional B lymphocytes.

Authors:  J G Karras; Z Wang; L Huo; R G Howard; D A Frank; T L Rothstein
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

8.  Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.

Authors:  Laura Mazzera; Manuela Abeltino; Guerino Lombardi; Anna Maria Cantoni; Roberto Ria; Micaela Ricca; Ilaria Saltarella; Valeria Naponelli; Federica Maria Angela Rizzi; Roberto Perris; Attilio Corradi; Angelo Vacca; Antonio Bonati; Paolo Lunghi
Journal:  Haematologica       Date:  2019-04-04       Impact factor: 9.941

Review 9.  IL-6 in inflammation, autoimmunity and cancer.

Authors:  Toshio Hirano
Journal:  Int Immunol       Date:  2021-03-01       Impact factor: 4.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.